GlassScriptPhysician profile
Michael F Conlin
NPI 1992735765
$40,365.62
in general payments reported to CMS, 2019-2025
42 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,820 · 2020: $1,449 · 2021: $2,276 · 2022: $2,035 · 2023: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Travel and Lodging: $1,531 · Food and Beverage: $1,241 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,900.00 |
| Travel and Lodging | $1,530.82 |
| Food and Beverage | $1,240.59 |
| Education | $114.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $27,158.44 | 2019-2023 | Repatha, Otezla |
| Amarin Pharma, INC. | $6,443.44 | 2019-2022 | |
| Novo Nordisk INC | $1,104.01 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $540.62 | 2019-2023 | Qulipta, Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $526.34 | 2019-2023 | Shingrix |
| Kowa Pharmaceuticals America, INC. | $473.34 | 2019-2023 | Livalo, Seglentis |
| Astellas Pharma US INC | $364.36 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $364.32 | 2019-2022 | |
| Lilly USA, LLC | $309.20 | 2019-2023 | Mounjaro |
| Sanofi-Aventis U.S. LLC | $284.45 | 2019-2022 | |
| Esperion Therapeutics, INC. | $278.44 | 2021-2023 | Nexletol |
| Novartis Pharmaceuticals Corporation | $235.44 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.62 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $218.08 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $215.48 | 2019-2023 | Austedo |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Conlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.